B72.3在卵巢癌中的临床研究及探针引导下的肿瘤定位

Clinical studies with B72.3 in ovarian cancer and probe-guided tumor localization.

作者信息

Del Vecchio S, Camera L, Petrillo A, Esposito G, Frasci G, Iaffaioli R V, Bianco A R, Salvatore M

机构信息

Nuclear Medicine Department, National Cancer Institute, Naples, Italy.

出版信息

Int J Rad Appl Instrum B. 1991;18(1):85-7. doi: 10.1016/0883-2897(91)90052-m.

DOI:10.1016/0883-2897(91)90052-m

PMID:2010311

Abstract

The present study reports the findings of radiolabeled monoclonal antibody (MoAb) application in the post-operative monitoring of patients with ovarian carcinoma. We studied 40 patients with histologically confirmed ovarian cancer using two radiolabeled MoAbs, 131I-B72.3 and 131I-OC125. Antibody scans showed that high uptake of radiolabeled MoAb was consistently associated with presence of disease confirmed by computed tomography, ultrasonography, clinical evolution and in a few cases by second look procedures. Computed tomography could not discriminate well between post-operative fibrosis and tumor lesion especially when localized in the peritoneum. We conclude that radiolabeled MoAbs, computed tomography and serum tumor markers are complementary in the postoperative monitoring of patients with ovarian carcinoma.

摘要

本研究报告了放射性标记单克隆抗体（MoAb）在卵巢癌患者术后监测中的应用结果。我们使用两种放射性标记的单克隆抗体131I - B72.3和131I - OC125对40例经组织学确诊的卵巢癌患者进行了研究。抗体扫描显示，放射性标记单克隆抗体的高摄取始终与计算机断层扫描、超声检查、临床病程以及少数情况下的二次探查手术所证实的疾病存在相关。计算机断层扫描在区分术后纤维化和肿瘤病变方面效果不佳，尤其是当病变位于腹膜时。我们得出结论，放射性标记单克隆抗体、计算机断层扫描和血清肿瘤标志物在卵巢癌患者的术后监测中具有互补性。